Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

Annals of Hematology

Volumn 90, Issue 4, 2011, Pages 379-387

  Candelaria, Myrna ^a   Herrera, Aquileo ^a   Labardini, Juan ^a   González Fierro, Aurora ^a   Trejo Becerril, Catalina ^a   Taja Chayeb, Lucía ^a   Pérez Cárdenas, Enrique ^a   De La Cruz Hernández, Erick ^a   Arias Bofill, Daymi ^a   Vidal, Silvia ^a   Cervera, Eduardo ^a   Dueñas Gonzalez, Alfonso ^a,b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Demethylating agent; Epigenetic therapy; HDAC inhibitors; Hydralazine; Myelodysplastic syndromes; Valproate

Indexed keywords

CYCLOSPORIN; DANAZOL; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDRALAZINE; MESTEROLONE; OXYMETHOLONE; PREDNISONE; THALIDOMIDE; TRANSKRIP; UNCLASSIFIED DRUG; VALPROATE MAGNESIUM;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; EPIGENETICS; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEG EDEMA; MALE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PRURITUS; RASH; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SOMNOLENCE; THROMBOCYTE COUNT; TREMOR;

EID: 79955701085     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1090-2     Document Type: Article

References (41)

1. Kasner MT, Luger SM (2009) Update on the therapy for myelodysplastic syndrome. Am J Hematol 84:177-186
2. Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Tota T (1997) Hypermethylation of the p15/INK4B gene in myelodysplastic syndromes. Blood 4:1403-1409 (Pubitemid 27355412)
3. Gore SD (2009) In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? Leuk Res 33(Suppl 2):S2-S6
4. List AF, Vardiman J, Issa JP, DeWitte TM (2004) Myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program 297-317.
5. Warlick ED, Smith BD (2007) Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches. Curr Cancer Drug Targets 7:541-558 (Pubitemid 47358141)
6. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospect for epigenetic therapy. Nature 429:457-463 (Pubitemid 38715140)
7. Daskalakis M, NguyenTT NC (2002) Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-aza- 2′deoxycytidine (decitabine) treatment. Blood 100:2957-2964
8. García-Manero G (2008) Demethylating agents in myeloid malignancies. Curr Opin Oncol 20:705-710
9. Shadduck RK, Latsko JM, Rossetti JM, Haq B, Abdulhaq H (2007) Recent advances in myelodysplastic syndromes. Exp Hematol 35(4 Suppl 1):137-143 (Pubitemid 46427991)
10. Kuendgen A, Lübert M (2008) Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol 87:601-611
11. Segura-Pacheco B, Trejo-Becerril C, Pérez-Cárdenas E et al (2003) Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 9:1596-1603 (Pubitemid 36554581)
12. Song Y, Zhang C (2009) Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemother Pharmacol 63:605-613
13. Law AY, Lai KP, Ip CK, Wong AS, Wagner GF, Wong CK (2008) Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Exp Cell Res 314:1823-1830
14. Wang X, Chao L, Jin G, Ma G, Zang Y, Sun J (2008) Association between CpG island methylation of the WWOX gene and its expression in breast cancers. Tumor Biol 30:8-14
15. Zambrano P, Segura-Pacheco B, Pérez-Cárdenas E et al (2005) A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 5:44
16. Chávez-Blanco A, Segura-Pacheco B, Pérez-Cárdenas E et al (2006) Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 6:2
17. Li H, Chen S, Shu Y, Chen Y, Su Y, Wang X, Zou S (2008) Synergy of DNA methylation and histone deacetylase inhibitors in the re-expression of RASSF1A and P16 genes silenced in QBC cells. Chin-Ger J Clin Oncol 7:627-630
18. Li H, Chen S, Shu Y, Chen Y, Su Y, Wang X, Zou S (2009) Effects of hydralazine and valproate on the expression of E-cadherin gene and the invasiveness and the invasiveness of QBC939 cells. Front Med China 3:153-157
19. Candelaria M, Gallardo-Rincón D, Arce C et al (2007) A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 18:1529-1538 (Pubitemid 47365487)
20. Arce C, Pérez-Plasencia C, González-Fierro A et al (2006) A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS ONE 1:e98
21. Dueñas-González A, Candelaria M, Pérez-Plascencia C, Pérez-Cárdenas E, de la Cruz-Hernández E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206-222
22. Candelaria M, Cetina L, Pérez-Cárdenas E et al (2010) Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynecol Oncol (in press)
23. Castañeda-Hernández G, Falcón-Neri A, Herrera-Abarca A, Herrera JE, Flores-Murrieta FJ (1995) Determination of three acetylator phenotypes in a Mexican population using sulfamethazine metabolic ratio. Am J Ther 2:57-60
24. Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) criteria in myelodysplasia. Blood 108:419-425 (Pubitemid 44061337)
25. Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, Shpilberg O (2010) 5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis. Hematologica 95:303-310
26. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U, Gattermann N (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266-1269 (Pubitemid 39166498)
27. Yang H, Hoshino K, Sánchez-González B et al (2005) Antileukemia activity of the combination of 5-aza-2?deoxycytidine with valproic acid. Leuk Res 29:739-748 (Pubitemid 40779480)
28. García-Manero G, Kantarjian HM, Sánchez-González B et al (2006) Phase 1/2 study of the combination of 5′aza-2-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279
29. Soriano AO, Yang H, Faderl S et al (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302-2308 (Pubitemid 47523148)
30. Blum W, Klisovic RB, Hackanson B et al (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25:3884-3891 (Pubitemid 47477265)
31. Kuendgen A, Bug G, Ottmann OG et al (2008) Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacitidine and valproic acid. Blood 12:3639
32. Raffoux E, de Labarthe A, Cras A et al (2008) Epigenetic therapy with 5-azacitidine, valproic acid and ATRA in patients with high-risk AML or MDS: results from the French VIVEDEP phase II study. Blood 112:763
33. Craddock C, Goardon N, Griffiths M et al (2008) 5-Azacitidine in combination with valproic acid induces complete remissions in patients with advanced acute myeloid leukaemia but does not eradicate clonal leukaemic stem/progenitor cells. Blood 12:945
34. Voso MT, Santini V, Finelli C et al (2009) Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 15:5002-5007
35. Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG, Gore SD (2008) p21 (WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 27:3615-3623 (Pubitemid 351793797)
36. Nishioka C, Ikezoe T, Yang J, Komatsu N, Koeffler HP, Yokoyama A (2009) Blockade of MEK signaling potentiates 5- aza-2′-deoxycytidine-induced apoptosis and upregulation of p21 (waf1) in acute myelogenous leukemia cells. Int J Cancer 125:1168-1176
37. Shen L, Kantarjian H, Guo Y et al (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605-613
38. Fandy TE, Herman JG, Kerns P et al (2009) Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114:2764-2773
39. Kuck D, Singh N, Lyko F, Medina-Franco JL (2010) Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation. Bioorg Med Chem 18:822-829
40. Klisovic RB, Stock W, Cataland S et al (2008) A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res 14:2444-2449 (Pubitemid 351551079)
41. Dueñas-González A, Vega MT, Martínez-Baños D, García-Hidalgo L, Sobrevilla P (2010) Response to hydralazinevalproate in a patient with mycosis fungoides. Case Report Med 2010:657579